Embed Size (px)
Citation preview
A company limited by guarantee
Registered in England and Wales 5403443
Registered charity number 1109743 (England and Wales)
Registered charity number SC 043478 (Scotland)
OVARIAN CANCER ACTION Annual Report and Audited Accounts For the Year Ending 31st March 2013
A company limited by guarantee
Registered in England and Wales 5403443
Registered charity number 1109743 (England and Wales)
Registered charity number SC 043478 (Scotland)
OVARIAN CANCER ACTION Annual Report and Audited Accounts For the Year Ending 31st March 2013
CONTENTS
• Facts about ovarian cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
• Public benefit statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
• Reference and administrative details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
• Report of the Chair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
• Report of the Board of Directors
Review against last year’s objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Highlights of 2012-13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Objectives for 2013-14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Financial review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Structure, governance and management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Statement of directors’ responsibilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
• Independent auditors’ report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
• Financial statements
Statement of financial activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Balance sheet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22
Notes for the financial statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23
• Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
• Globally each year 225,000 women are diagnosed with ovarian cancer,
which makes it neither a rare nor a common cancer.
• In the UK a woman dies from ovarian cancer every two hours and it remains
the most deadly of the gynecological cancers.
• Five year survival for ovarian cancer has increased from 33% to 44%, though
overall the mortality rate remains unchanged.
• Ovarian cancer has a very high rate of recurrence; the disease recurs in
between 70 and 90% of cases compared with just 22% for breast cancer.
• A third of UK women with the disease are diagnosed as an
emergency admission.
• Survival rates for women with ovarian cancer in the UK lag behind
those of other developed counties.
FACTS ABOUT OVARIAN CANCER
4
We pay tribute to the incredible work of Robert C. Bast,Jr, MD who discovered the CA125 blood test on behalf of all women with
ovarian cancer. The advice and guidance he has given to Ovarian Cancer Action has shaped our organisation.
The last five years have seen remarkable developments
in our understanding of the complexity of ovarian
cancer: there is an outstanding level of cooperation and
willingness to share ideas amongst those in the
ovarian cancer research field worldwide and this
cooperation bodes well for the women whose
lives we want to improve.
However, the cure rate for women with epithelial
ovarian cancer has changed little since platinum-based
treatment was introduced over 30 years ago.
There have been large scale screening trials
in USA, Australia and UK, and both the American and
Australian studies have concluded that the screening of
healthy populations do more harm than good overall.
The UK study – which uses a novel trial design and
has more encouraging preliminary data – is due to
report in 2015.
There have also been a number of stratified studies
of ovarian cancer; these have demonstrated that it is a
far more complex disease than previously realised and
one which can originate not only in the ovaries but also
in the fallopian tubes.
Some sub-groups of the disease do not respond to the
standard chemotherapy, and alternative treatments are
needed for women with these sub-types.
Despite the plethora of research dedicated to the
mechanisms of platinum resistance (one of the key
challenges for ovarian cancer survival), it is yet
to be translated to clinical practice.
WHERE WE ARE TODAY
5
What I like about OCA is that they allow their Voices the opportunity to make a contribution in so many different ways. You are there
for patients who feel they have been cast adrift after treatment and are at a complete loss. And the Research Centre gives us hope.
That very word is the most important one in my vocabulary these days.
ANGELA WALKER LONG TERM SUPPORTER OF THE CHARITY
We are now campaigning and, where possible, funding
proposals that creatively and innovatively address
one of the provocative questions proposed at the last
meeting of the Helene Harris Memorial Trust (HHMT),
our highly regarded international forum on ovarian
cancer. Our last gathering brought together over fifty
thought leaders and produced a paper published
in Nature Reviews Cancer in 2011 called “Rethinking
Ovarian Cancer: Recommendations for Improving
Outcomes” Vaughan S et al, Nature Reviews Cancer 11:719, 2011.
Current specific research challenges:
1 / Risk Reduction in targeted populations – There
is a growing knowledge base on how mutations in
a variety of genes increase the risk of subsequent
ovarian cancers. Do specific mutations lead to
rational strategies for prevention in specific high risk
populations?
2/ Novel strategies in preventing or reversing drug
resistance – Platinum sensitive ovarian cancer is
typically a non-lethal disease, yet essentially all
women with recurrent disease will develop platinum
resistance. Are there innovative ways to reduce the
clonal evolution towards platinum resistance?
3/ Optimising treatment strategies for recurrent
disease – Is there an optimal strategy for
maximising quality of life and/or survival?
4/ Cancers arising in the ovary have a variety of
different histologies, each with a different set of
genetic underpinnings –
Can strategies be developed to define predictive
biomarkers (or imaging strategies) that will
improve the ability to diagnose and/or manage
the development of more precise therapies for an
individual with ovarian cancer?
5/ Is the bilateral salpingectomy procedure (removal
of the fallopian tubes) a reasonable substitute for
bilateral oophorectomy (preventative removal of
the ovaries) and is the salpingectomy procedure a
high risk for “ovary cancer”?
6/We now know some ovarian cancer cell line
models can no longer be used. Can innovative
experimental in vivo or ex vivo models serve as
better tools for developing novel therapeutic
strategies in the management of ovarian cancer?
CAMPAIGNING FOR FURTHER RESEARCH
6
I’m proud to be able to make use of my experiences through OCA to help others understand and improve
treatment for ovarian cancer. Whenever I have done so I’ve always felt incredibly well supported by OCA.
CAROLINE RAPHAEL LONG TERM SUPPORTER OF THE CHARITY
Purpose
• Ovarian Cancer Action strives to stop women dying from ovarian cancer. We fund world-class scientific
research leading to innovative treatments and progressive surviorship solutions.
• Ovarian Cancer Action campaigns to ensure women and healthcare providers know the risk factors,
symptoms and treatment options to enable informed and rapid action. Fundamentally we demand that
every woman should have the best treatment available.
Values of Ovarian Cancer Action
Our research funding and campaigning work is underpinned by the fundamental idea that the future can
and will change.
We believe that:
• Women with ovarian cancer deserve more attention than they currently receive;
• Good quality therapies need to be found that will permanently control the disease;
• Women with ovarian cancer should be given the best possible information about therapeutic options
and service providers in order to make informed choices;
• All women with ovarian cancer should be offered genetic testing;
• Treatments that put quality of life first are of paramount
importance;
• UK women deserve the best quality treatment the world has
to offer – including the avoidance of unnecessary procedures;
• The speed of scientific progress needs to be accelerated to
stop women dying;
• Every woman should know the symptoms of ovarian cancer.
The Directors consider that all the aims and objectives detailed
in this report are in order to benefit the public.
The Directors consider they have complied with their duty in
Section 17 of The Charities Act 2011 and have due regard to the
public benefit guidance published.
PUBLIC BENEFIT STATEMENT
7
The Board of Directors and staff of OCA would like to pay tribute to two dedicated and
passionate Voices, Loretta Oliver and Rocky Scott, who lost their fight to ovarian cancer in 2013.
Ovarian Cancer Action
A company limited by guarantee
Registered in England and Wales 5403443
Registered charity number 1109743
(England and Wales)
Registered charity number SC 043478
(Scotland)
8-12 Camden High Street
London NW1 0JH
Telephone: 0207 380 1730
E-mail: [email protected]
www.ovarian.org.uk
Directors
Allyson J. Kaye (Chair)
Daniel B. Harris
John E. Harris CBE
Martin D. Paisner CBE
Emma J. Scott
Lord Turnberg
Jenny Knott (Appointed 11 June 2012)
Honorary Patrons
The Hon. Nigel Havers
Lord Jones of Birmingham
Dr Chris Steele MBE
Gwyneth Strong
Company Secretary
Daniel B. Harris
Auditors
Wilson Wright LLPChartered AccountantsThavies Inn House3-4 Holborn CircusLondon EC1N 2HA
Legal Advisors
Squire Sanders LLP7 Devonshire SquareLondon EC2M 4YH
Accountant and honorary Treasurer
Nicholas Kaye FCAAEL Partners LLP201 Haverstock Hill London NW3 4QG
Bankers
National Westminster Bank PLC1-4 Berkeley Square HouseBerkeley SquareLondon W1A 1SN Coutts & Co440 StrandLondon WC2R 0QS
Staff
Gilda Witte, Chief Executive
Nina Gopal, Head of Fundraising
Tania Pearson, Head of Communications
and Public Affairs (till Oct)
Lucinda Watson, Head of Marketing (from October)
Abi Begho, Healthcare Projects Manager
Louise Vale, Trusts Fundraiser
Emily Legg, Corporate Fundraiser
Charlotte Sewell, Community Fundraiser
Laura McGurl, Press Officer
Leila Hermansson, PA and Office Manager
Kim Broodie, Finance Officer
8
REFERENCE AND ADMINISTRATIVE
As the UK’s leading ovarian cancer charity, OCA is committed to tackling this disease on a broader front
to transform the lives of the hundreds of women diagnosed each year with ovarian cancer.
I am happy to report that the second five year programme has now started at the Ovarian Cancer
Action Research Centre (OCARC) and we look forward to working more closely with our international
counterparts and driving forward scientific innovation.
Earlier this year, with the help of the OCARC, we achieved a world first by fitting a cancer patient with
the Alphapump©, a device which drains malignant ascites from the stomach to the bladder, where it is
naturally expelled. The device invented by Sequana Medical potentially represents research benefits and
major improvements in quality of life for women with ascites.
The Platinum Resistance project has had some very promising results from its stage 1 clinical trials, and
the plans for 2013 are very exciting.
One project yet to be commenced from the last round of scientific funding will not be going ahead.
The funds originally allocated to this project will be set aside for commissioned work via a response
mode grant round, to reflect the priorities of the HHMT think tank paper “Nature Reviews Cancer:
rethinking ovarian cancer.”
In 2013 we registered for full charitable status in Scotland, which reflects our funding of scientific
programs that reach across the whole of the UK. The BRITROC collaboration reflects our ambition to
include scientists and researchers countrywide.
Our campaigning work has also had a very successful year. We are working with the Department of Health
cancer prevention team on the UK’s first ovarian cancer pilot – as part of ‘Be Clear on Cancer’ initiative.
We have also continued to push for symptoms awareness amongst GPs and the general public.
In the last month of our financial year we spearheaded a new initiative about hereditary disease: our
March campaign for Ovarian Cancer Awareness Month “know your family cancer history,” was reported
on national television, BBC Radio, press and internet. This was reinforced in May 2013, when the actress
Angelina Jolie publicly announced that she carries the BRCA gene mutation. We have been vocal about
the USA Supreme Court ruling on the BRCA gene patent and are pushing ahead with the broader ethical
issues around genetic and hereditary disease.
We have received excellent PR throughout the year and would like to thank the Ovarian Cancer Voices
for telling their stories with such passion and frankness. Their honesty remains critical to conveying
this message.
Our governance processes have been improved with the introduction of a key measurement performance
dashboard. My thanks, as ever, to the Board who continue to contribute wisely and vociferously to the
challenges of tackling ovarian cancer.
The charity has achieved so much this year, my thanks go to the donors, funders, researchers, Ovarian
Cancer Voices and scientific advisors as well as to the Charity’s small office team.
9
REPORT FROM THE CHAIR
Allyson Kaye
Chair, Board of Directors
Date: 9 September 2013
REPORT OF THE BOARD OF DIRECTORS
Review against last year’s objectives
Last year we said we would:
Funding Research
• Implement a new research strategy with the Ovarian Cancer Action Research Centre
• Launch 8 BriTROC research programmes in centres of excellence across the UK
• Communicate the latest science on ovarian cancer to the widest possible audience
Awareness
• Reach our targeted UK audiences with symptoms awareness
• Participate in ovarian cancer awareness month
• Evaluate our programme of GP contact
• Continue to lobby the Government to promote symptoms awareness
Voices
• Increase the number of Voices working with the charity
• Implement training and induction for the Voices
Governance
• To deliver a Vision and Five Year Strategy post scientific review
• To review the website and make it more accessible
• To review business processes to ensure best practice
As an active supporter of Ovarian Cancer Action, I am extremely pleased with the progress that has been made in the past year. Thanks to the hard work and dedication of the charity, people are more aware of the symptoms of ovarian cancer and the urgency of the problem is better known.
JAS MALHILONG TERM SUPPORTER OF THE CHARITY
achieved
achieved
achieved
achieved
achieved
achieved
achieved
achieved
achieved
achieved
achieved
achieved
10
OVARIAN CANCER ACTION’S KEY ACHIEVEMENTS OVER THE PAST FEW YEARS
Our Research Centre was founded in 2006 and is still the UK’s only dedicated ovarian cancer
research institution. It is a world leader, driving ground-breaking research, and we’re constantly
working to raise awareness of ovarian cancer and its symptoms.
• Ovarian Cancer Action (OCA) is founded by Allyson Kaye as a campaigning organisation to raise
awareness of the disease amongst women and to fight for symptom recognition.
• The Ovarian Cancer Action Research Centre (OCARC) is founded, following a competitive review,
in partnership with Imperial College London, Hammersmith Hospital, the Royal Marsden Hospital
and the Institute of Cancer Research.
• OCA is awarded the first government grant of £46,000 to raise awareness of the symptoms
of ovarian cancer
• OCA conducted the first national ovarian cancer awareness campaign, distributing leaflets and
posters to every GP surgery.
• OCA is awarded two key strategic grants of £1 million each from The Freemasons’ Grand Charity
and The Maurice Wohl Charitable Foundation.
• The OCARC relocated to new, expanded laboratories.
• The Department of Health ratified key messages on ovarian cancer symptoms.
OCA launched a national advertising campaign around these symptoms.
• The number of OCA Voices increased to over one hundred across the UK.
• The charity’s growth prompted a move to its current offices in central London.
• Having completed its first clinical trial (with GlaxoSmithKline) the OCARC was awarded a GSK
Gold Award for the fastest trial to recruit its first patient and the fastest trial to complete.
• OCA partnered with the National Institute of Health and Care Excellence to promote the launch
of the first NICE guidelines on the diagnosis of ovarian cancer which instructed GPs to test women
over 50 with symptoms of ovarian cancer.
• The charity’s 12th international conference led to the creation of a nine point action plan
Rethinking Ovarian Cancer which was published in the journal ‘Nature Reviews Cancer’.
• OCA launched BriTROC (British Translational Research in Ovarian Cancer Consortium), the first
UK-wide collaboration on ovarian cancer research which involves eight centres around the UK.
• The Research Centre had a scientific five-year review conducted by an international panel of
experts which concluded: ‘The project is ambitious and the proposal is innovative and insightful.
This is important work and if it can be achieved, this is the team which will do it.’
• The world’s first cancer patient was fitted with an Alfapump®. Developed with the OCARC, this is
a mechanism for managing malignant ascites (abdominal fluid).
• During Ovarian Cancer Awareness Month a Fact File and online learning module were sent to GPs
across the UK in partnership with GP magazine. A major press campaign resulted in press coverage
with a potential audience reach of over 11 million.
2007
2008
2009
2010
2011
2012
2013
2006
2005
11
The Research we fund
Ovarian Cancer Action funds translational research
projects that will swiftly bring better treatment
options to women.
We established the Ovarian Cancer Action Research
Centre six years ago to enable concentrated and
sustained focus on research around ovarian cancer
which could have a high clinical impact.
To date over £6 million has been invested.
Alfapump
The Ovarian Cancer Action Research Centre
implanted an alfapump® system into a woman with
advanced ovarian cancer to manage malignant
ascites (fluid in the abdomen), a world first.
The alfapump is a battery-operated mechanical
device which drains fluid from the abdomen into the
bladder where it is expelled naturally in the urine,
vastly improving the woman’s quality of life.
A randomised patient trial is planned later this year.
BriTROC
We are funding the UK’s first scientific collaboration
on ovarian cancer, the British Translational Research
Ovarian Cancer Collaborative (BriTROC). BriTROC
aims, through tissue analysis, to provide a better
understanding of the different histological subtypes
of ovarian cancer.
At present biopsies of ovarian cancer tumours are
only taken at the point of diagnosis which makes it
difficult to analyse how the cancer develops in later
stages. Initially eight cancer research centres across
the UK will collect biopsy samples of ovarian cancer
cells during and after treatment to monitor the
progression of individual cancers.
Platinum resistance
We have completed the first stage one clinical trial
targeting the AKT inhibitor as a target for aquired
platinum resistance. The results are very encouraging
and we are moving forward to a larger trial.
RESEARCH HIGHLIGHTS 2012/13
In 2012/13 Ovarian Cancer Action committed over £1 million to scientific research
BriTROC is the first ever UK - wide ovarian cancer scientific research collaboration. We are proud to be part of this initiative
The inspiration we both got from attending the Research Centre for the Tribute Wall event, seeing how committed the researchers are, and the developments that are moving left us feeling even more motivated. This is one reason that we support OCA, the other is to stop
this terrible disease that claimed our mother.
HELEN WITTER AND LYNDA ROBERTSLONG TERM SUPPORTERS OF THE CHARITY
12
Highlighting Genetic Cancer
This year’s campaign for Ovarian Cancer Awareness
Month in March was to highlight genetic and
hereditary cancer. We called for all women to check
their family medical history and if more than one
close family member has had breast or ovarian
cancer, to talk to their GP about genetic testing.
GP mailing
Following the review of the GP mailing we partnered
with GP Magazine and produced a GP Fact file.
This was then converted into an online training credit
for GPs.
Be Clear on CancerIn January 2013 the Department of Health ran a three
month pilot in six cancer networks to trial growing
public awareness of ovarian cancer symptoms as part
of its ‘Be Clear on Cancer Campaign’. Ovarian Cancer
Action worked with a number of charities including
CRUK to help develop the materials and train local
communicators. An Ovarian Cancer Action Voice Lou
Pescod was featured in their advertising.
Ovarian Cancer Action led the collaboration between
The Eve Appeal, Ovacome and Target Ovarian Cancer
to call on the Government to extend the pilot into a
full regional trial.
Awareness Film
We launched our new awareness video using real
women who have had ovarian cancer and their
families. The film talks very emotionally about
symptoms and recognising them early enough,
and has had over 4000 views.
We translated our symptoms leaflets into 5 new
languages: Hindi, Punjabi, Chinese, Polish, and Turkish.
Collaboration
We teamed up with the Association of Continence
Advice, the London Health Improvement Board,
Bowel Cancer UK, Jo’s Cervical Cancer Trust,
Haymarket Publishing, and The National Assembly
for Wales, Keep Well Scotland and Prostate Cancer
UK to raise awareness. We also continued to engage
with NAEDI, Cancer Research UK, the Department of
Health, NICE, The Eve Appeal, Target Ovarian Cancer
and Ovacome.
AWARENESS HIGHLIGHTS FROM 2012/13
13
This achieved exceptional coverage on BBC and ITV Breakfast TV, national radio on BBC Radio 5 Live and Radio 2 as well as national newspapers, local radio and the internet.
34,000 GP Fact Files were sent to GPs in the UK
More about ovarian cancer• Around5,800womenarediagnosedwithovariancancerinEnglandeachyear–around
4,750ofwhom(morethan80%)areaged50andover• Morethan3,350womenaged50andoverdiefromovariancancerinEnglandeveryyear• Over90%ofallwomendiagnosedwiththeearlieststageovariancancer(stageI)survive
foratleastfiveyears.Thisfigureis5%forwomendiagnosedwiththemostadvancedstagedisease(stageIV)
Who is most at risk of developing ovarian cancer?
Women:
• aged over 50 – the risk of developing ovarian cancer increases with age
• with a family history of ovarian, breast and/or other cancers
‘BloatingwasthemainsymptomformebutIputitdowntogettingolder.Ipointeditouttomysisterand she urged me to see a GP. My advice to anyone with persistent bloating is to take yourself straight to the doctor.’Lou Pescod, aged 65, supporter of Ovarian Cancer Action
Opening conversations about cancer can be difficult, are there any tips?
‘Find phrases that you are comfortable with and practise using them,’ says a Cancer Research UK cancer nurse. ‘For example, if you wanted to mention cancer as part of a medicine review, mentioning it in the same breath as heart disease, stroke and diabetes may make it easier.’
‘If you are worried about someone who has repeatedly bought over the counter medicines for persistent bloating, you could ask them “Do you think it might be a good idea to discuss your symptoms with your GP?”’
Be prepared to take your customer into a consultation room for more privacy or have any sensitive conversations in a way that other customers will not be able to overhear.
Pharmacy staff who feel uncomfortable talking about cancer should seek the advice of their pharmacist.
How are GPs and hospitals preparing for the campaign?
Local NHS teams are working with GPs and Trusts in your area to help them prepare for the campaign. There are additional briefing sheets for GPs and their practice teams, which highlight the recent NICE guidelines and diagnostic tests available to them.
‘This campaign is a great opportunity to have a more detailed conversation with women about symptoms they might ignore because of theirage.Pharmacistsandtheirteamscanlookoutforwomenover50whoregularlybuyoverthecountermedicinesforpersistentbloating.Andthey can help by directing women they are concerned about to their GPs.’Dermot Ball, MRPharmS
Three things you can do
1 Be mindful. Many women you talk to may have seen the campaign and want to discuss it during regular consultations, such as medicine-use reviews, or when buying relevant OTC medicines. Or you could mention it when you advise about management of relevant symptoms.
2 Give permission. People may not realise their symptoms are serious; may worry about wasting the GP’s time; or may be embarrassed. They might seek permission to make an appointment. You may see some customers or patients more regularly than their doctor does. Where relevant, encourage women to visit their GP. If you feel comfortable, suggest they mention that their pharmacist or a member of the pharmacy team sent them. It may be the push they need to get themselves checked out.
3 Promotethecampaign.You can order free posters and leaflets to display in your pharmacy from the Department of Health via www.orderline.dh.gov.uk or by ringing 0300 123 1002. Your local Cancer Network will be able to tell you more about the planned activities in your area and how you can help. Chat to customers and colleagues about the campaign – talking may prompt someone to open up about a symptom they didn’t think was serious.
Find out more
• From January, the public-facing website for Be Clear on Cancer is www.nhs.uk/persistentbloating
• Informationandresources for pharmacy teams are available at: www.naedi.org/ beclearoncancer/ovarian
The NHS is piloting a local campaign to
raise awareness of persistent bloating
as a symptom of ovarian cancer – you
can help make it a success.
What is Be Clear on Cancer?
Be Clear on Cancer aims to improve early diagnosis of
cancer by raising awareness of symptoms and encouraging
people to see their GP earlier.
The Department of Health prioritises cancer types based
on the number of deaths that could be avoided if survival
rates matched the best in Europe. It then reviews the
latest evidence and engages with experts to develop key
messages for the campaigns, testing them locally and
regionally, before they are rolled out nationally.
What is the campaign’s key message?
The message for women is: Feeling bloated, most
days, for three weeks or more could be a sign of
ovarian cancer.
Who is it aimed at?
All women aged 50 and over, the age group most at risk of
developing ovarian cancer, and their key influencers, such as
friends and family.
Why focus on persistent bloating?
Focusing on just one key symptom keeps the message
simple and direct. The Department of Health consulted
with experts and clinicians who felt that, of the symptoms
highlighted in the recent NICE guidelines, this was the key
possible sign of ovarian cancer.
Why does the campaign say ‘most days, for three
weeks or more’?
When tested with the target audience, women felt the
campaign needed to explain what was meant by ‘persistent’.
They asked for clarity – to know how long they should wait
before going to see their GP.
What’s happening in your local area and when?
Local NHS teams are working with the Department of Health
to develop a range of activities aimed at reaching women in
your communities. Individual activities vary across each of
the local pilots, but will include media such as local press and
radio in some areas and community-based outreach work in
others. These will be taking place from 14 January to
mid-March 2013.
Why do you need to know about the campaign if it
prompts women to see their GP?
Pharmacists and their teams have a crucial role to play in this
local campaign.
We know that people delay going to see their GP for a variety
of reasons. You can help signpost women aged 50 and over
with the key symptom to their GP.
You may be aware of women over 50 who repeatedly buy
over the counter (OTC) medicines for persistent bloating or
they may ask your advice about this symptom. They could
attribute it to getting older or things such as irritable bowel
syndrome (IBS), but IBS rarely presents for the first time in
women of this age.
We know that many people like the informal environment of
the pharmacy and may be willing to discuss their symptoms
or worries more easily in this setting. If appropriate, suggest
they get them checked out by their GP.
Ovarian cancer: How
pharmacy teams can
support the campaign
naedi.org/beclearoncancer/ovarian
Supported
byGateway reference number 18329
Lou Pescod, cancer survivor
Women V Cancer
This consortium cycling challenge
concept entered a second year and
once again delivered an incredible
income for the three benefitting
charities – Ovarian Cancer Action,
Jo’s Cervical Cancer Trust and
Breast Cancer Care. A total of 254
extraordinary women cycled 350
km in three groups through rural
India. Women V Cancer is now an
established annual event with the series
next moving to Cuba and then China.
“It started just about raising money for three
fantastic charities, but I now have made lifelong
friends with some incredible women who have shared
a unique experience” – Emily (India, Group 3).
The Wonderball at The Savoy
Starting with
a champagne
reception, 322
guests enjoyed
a three course
dinner, entertainment
from Spandau Ballet’s
Tony Hadley, and dancing
till 1am in the beautiful setting of The Savoy. This,
the charity’s first ball, was made possible thanks to
support from M&S and the generosity of numerous
companies and individuals who donated an array of
items for a wonderful auction and raffle, with prizes
ranging from a Jenny Packham dress to lunch with
Joanna Lumley.
Carrying the torch for ovarian cancer
When Jane Daly was recognised at the M&S Plan A
Employee Volunteer Awards as the winner of
Outstanding Fundraising Act for her tireless efforts to
raise funds and the profile of ovarian cancer at M&S,
the prize was to be part of Olympic
history. Jane, who
with M&S has now raised over
£500,000 for the charity, carried
the Olympic torch in May just
ahead of Didier Drogba. “I
hope the torch relay raises
awareness of ovarian cancer
and the invaluable work being
done by M&S, Ovarian Cancer
Action and all their supporters”-
Jane Daly.
Walkathong 2012
It started in 2011 with a walk in the woods but in
2012 it went global. The second annual Walkathong
took place on 1 July on the beautiful Ashridge
Estate. Around the world, Cary’s friends and Ovarian
Cancer Action supporters also took part by taking
photographs in teal knickers to show their support.
“From the Great Wall of
China to the Golden Gate
Bridge, wherever our
teal knickers have
been seen they’ve
raised a smile. I
never dreamt they
could be such a
powerful way to
raise awareness of
the symptoms
of ovarian cancer”
– Cary Cochrane
Long term supporter.
Legacies
We would like to thank the selfless generosity of
those who have bequeathed some or part of their
estate for our work this year. These donations
are crucial in relation to our long term planning.
Particular gratitude is extended to the late Tessa Jane
Sidey and the late Carol Ann Abery whose bequests
are the largest received by the charity to date.
FUNDRAISING HIGHLIGHTS 2012/13
14
PLANS FOR THE FUTURE
Objectives for 2013/14
Research
• Work with the Ovarian Cancer Action Research
Centre to drive the research programme
• Run a highly effective grant application process,
updating the systems to deliver best practice
• Set up a lay panel to review research
• Work with BriTROC to ensure its success
• Start planning the next HHMT meeting
• Communicate the latest science in the field
of ovarian cancer as widely as possible
Awareness
• To continue to campaign around hereditary and
genetic disease
• To participate in ovarian cancer awareness
month
• To devise a new strategy for communicating
with GPs
• To work with Government and other cancer
charities to deliver awareness and symptoms
message
• To find new ways to communicate the work that
the charity does
Voices
• To grow the number of active Voices working
with the charity, especially outside London
• To set up a lay research panel and provide
appropriate training and support
• To better involve existing Voices in more aspects
of the charity’s work
Governance
• To build on best practice by regularly reviewing
processes
• To build on and review the key metric indicators
• To build access to broader professional services
15
It’s fantastic that Ovarian Cancer Action are transforming ovarian cancer into national headline news. More people need to be aware of this rare cancer; the cost of individual lives,
and the cost to the nation in managing a disease for which there is no known cure.
ANNIE MULHOLLAND LONG TERM SUPPORTER OF THE CHARITY
FINANCIAL REVIEW
Financial Activities
The Directors are delighted to report that the
charity’s incoming resources amounted to £2,334,827,
(2012 – £1,848,602).
The Directors would like to thank all those volunteers
and donors – corporate, trusts and foundations, as
well as individual donors who have supported the
charity in increasing numbers over the past year and
upon whom we are dependent.
The charity’s income was underpinned by two
substantial grants of £1 million, each paid in equal
instalments over five years, made by the Maurice
Wohl Charitable Foundation and The Freemasons
Grand Charity. The Directors would like to place on
record their grateful thanks to the Trustees, staff
and supporters of these organisations for their
commitment to the charity’s work. Income includes
legacies of £663,377.
Total expenditure on charitable activities (research,
awareness raising and giving a voice) amounted to
£1,702,936 (2012 – £1,457,796). The Directors were
delighted to be able to make additional research
grants totalling £850,000 to fund new work at the
Ovarian Cancer Action Research Centre, as well as a
grant to the BriTROC consortia of £380,000, taking
our investment into research to over £1 million for
the financial year. As a result of these activities, the
charity achieved a surplus of £225,957
(2012 – £24,645).
Principal Funding Sources
A detailed breakdown of funding sources is given in
Note 3 to the Financial Statements.
Reserves Policy
In accordance with Charity Commission guidance, free
reserves are uncommitted reserves freely available
which exclude restricted and designated funds and
amounts invested in tangible fixed assets. Designated
funds arise when the Directors set aside unrestricted
funds for specific purposes. Restricted funds arise
when conditions are imposed by the donor, or by the
specific terms of appeal, and can only be spent on the
activities specified.
Ovarian Cancer Action relies almost entirely on
voluntary income, which is subject to fluctuation.
In order to ensure the continuance of the charity’s
day-to-day activities, the Directors have established
a policy to hold free reserves equivalent to at least
three months’ expenditure excluding grants and
expenditure from restricted funds planned for the
year ahead. At 31 March 2013 the Charity held total
reserves of £1,656,495 (2012 – £1,430,538).
These were split into restricted, designated and
general funds.
At 31 March 2013, restricted funds amounted
to £167,705 (2012 – £4,000). At 31 March 2013,
designated funds amounted to £1,383,000 (2012 –
£1,230,834); these were funds set aside to fund future
research expenditure. The amount of the general fund
available as a reserve agains fluctuating income, at
31 March 2013, was £92,106 (2012 – £175,179). This
amounted to three months of forecast unrestricted
non grant expenditure and thus complied with the
reserves policy established by the Board.
The breakdown of the reserves between restricted,
designated and general funds is shown in Note 15 to
the Financial Statements.
16
STRUCTURE, GOVERNANCE & MANAGEMENT
Legal Entity
Ovarian Cancer Action is a company limited by
guarantee registered as a company in England and
Wales on 24th March 2005, and as a registered
Charity in England and Wales on 27th May 2005. Its
governing document is the Memorandum and Articles
of Association.
Organisational Structure
Ovarian Cancer Action is governed by a Board of
Directors whose responsibilities include setting the
strategic direction and goals of the Charity and
providing effective governance. The Board meets four
times a year. The Chief Executive is supported by a
small team of staff, with a full-time equivalent of 11
employees at the year-end.
Role and Contribution of Volunteers
Nicholas Kaye FCA of AEL Partners LLP provides
all financial book keeping on a pro bono basis. The
charity also receives pro bono support from the
advertising agency Rainey Kelly Campbell Roalfe Y&R
and the media agency MPG. Ovarian Cancer Action
is indebted to all those supporters who play a vital
role in raising awareness of ovarian cancer in their
communities, in the local and national media, and by
raising funds for our work.
Appointment, Induction and Training of Directors
New Directors are appointed by the Board of
Directors and must be re-appointed by the members
at the first annual general meeting following their
appointment to be able to continue to serve. All
Directors must be members of Ovarian Cancer Action.
Each new Director attends an induction session with
the Chief Executive to confirm the role, responsibilities
and expectations of Directors and highlight current
governance and strategic issues. The session includes
an overall view of the history of the organisation,
current activities and future plans.
Grant-Making Policies
Ovarian Cancer Action invites applications for
research funding from within and outside the Ovarian
Cancer Action Research Centre. All grant applications
are subject to rigorous peer review by the Medical
Science Review Committee (MSRC), which is an
international, independent group of ovarian cancer
research specialists chaired by Professor Bob Bast,
Vice-President of Translational Medicine at the
University of Texas MD Anderson Cancer Center.
Relationships with Other Charities
The Board of Directors actively seeks to collaborate
with other charities where this will accelerate
improvements in survival. Ovarian Cancer Action
played a leading role in the establishment of
Ovarian Cancer Awareness Month (OCAM) in the
UK. Membership is held at Cancer 52, The Cancer
Campaign Group, the Association of Medical Research
Charities and the Fundraising Standards Board.
Risk Management
The Board of Directors monitors the principal business
and control risks to the charity and has completed a
formal risk assessment.
Directors
The Board of Directors during the year and at the
date of signing this report are listed on page 8 as
are the company and charity numbers of Ovarian
Cancer Action.
17
STATEMENT OF DIRECTORS’ RESPONSIBILITIES
The Directors are responsible for preparing the
Directors’ Annual Report and the financial statements
in accordance with applicable law and United
Kingdom Accounting Standards (United Kingdom
Generally Accepted Accounting Practice).
Company law requires the Directors to prepare
financial statements for each financial year which
give a true and fair view of the state of affairs of
the charitable company and of the incoming
resources and application of resources, including the
income and expenditure, of the charitable company
for that period.
In preparing these financial statements, the Directors
are required to:
• Select suitable accounting policies and then
apply them consistently;
• Observe the methods and principles in the
Charities SORP;
• Make judgments and estimates that are
reasonable and prudent;
• State whether applicable UK Accounting
Standards have been followed, subject to any
material departures disclosed and explained in
the financial statements; and
• Prepare the financial statements on the going
concern basis unless it is inappropriate to
presume that the charitable company will
continue in business.
The Directors are responsible for keeping proper
accounting records that disclose with reasonable
accuracy at any time the financial position of the
charitable company and which enable them to ensure
that the accounts comply with the Companies Act
2006, the Charities and Trustee Investment Act 2005
and the Charities Accounts (Scotland) Regulations
2006 (as amended). They are also responsible for
safeguarding the assets of the charitable company
and hence for taking reasonable steps
for the prevention and detection of fraud and other
irregularities.
In so far as the Directors are aware:
• There is no relevant audit information of which
the charitable company’s auditor is unaware; and
• The Directors have taken all steps that they ought
to have taken to make themselves aware of any
relevant audit information and to establish that
the auditor is aware of that information.
The Directors are responsible for the maintenance
and integrity of the corporate and financial
information included on the charitable company’s
website. Legislation in the United Kingdom
governing the preparation and dissemination of
financial statements may differ from legislation in
other jurisdictions.
AUDITORS
The auditors, Wilson Wright LLP, will be proposed for
reappointment in accordance with Section 485 of the
Companies Act 2006.
Signed on behalf of the Board
Allyson J. Kaye
Chair, Board of Directors
Date: 9 September 2013
18
As a family we were deeply impressed by our visit to the Ovarian Cancer Research Centre. The complete dedication of the scientists and doctors was clear to us immediately and, although some
of the science was over our heads, we could see that progress is being made on a broad front by addressing every aspect of the disease, it’s diagnosis and treatment, using state of the art equipment
JOHN HAYWARDLONG TERM SUPPORTER OF THE CHARITY
OVARIAN CANCER ACTION
Independent Auditors’ report to Directors and members of
Ovarian Cancer Action
We have audited the financial statements of Ovarian Cancer Action for the year ended 31 March 2013
which comprise the Statement of Financial Activities, the Summary Income and Expenditure Account,
the Balance Sheet and the related notes. The financial reporting framework that has been applied in their
preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally
Accepted Accounting Practice).
This report is made exclusively to the members, as a body, in accordance with Chapter 3 of Part 6 of
the Companies Act 2006, and to the charity’s directors, as a body, in accordance with Section 44 (1) (c)
of the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts
(Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the
members and the charity’s directors those matters we are required to state to them in an auditors’
report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the charity, its members as a body and its directors as a body, for
our audit work, for this report, or for the opinions we have formed.
Respective responsibilities of directors and auditor
As explained more fully in the Directors’ Responsibilities Statement set out in the Directors’ Report,
the trustees (who are also the directors of the charitable company for the purposes of company law)
are responsible for the preparation of the financial statements and for being satisfied that they give a
true and fair view.
We have been appointed as auditors under section 44(1)(c) of the Charities and Trustee Investment
(Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations
made under those Acts.
Our responsibility is to audit and express an opinion on the financial statements in accordance with
applicable law and International Standards on Auditing (UK and Ireland). Those standards require us
to comply with the Auditing Practices Board’s (APB’s) Ethical Standards for Auditors.
Scope of the audit of the financial statements
An audit involves obtaining evidence about the amounts and disclosures in the financial statements
sufficient to give reasonable assurance that the financial statements are free from material misstatement,
whether caused by fraud or error. This includes an assessment of: whether the accounting policies
are appropriate to the charitable company’s circumstances and have been consistently applied and
adequately disclosed; the reasonableness of significant accounting estimates made by the trustees;
and the overall presentation of the financial statements. In addition, we read all the financial and
non-financial information in the Chairman’s and Directors’ Reports to identify material inconsistencies
with the audited financial statements. If we become aware of any apparent material misstatements or
inconsistencies we consider the implications for our report.
19
OVARIAN CANCER ACTION
Independent Auditors’ report to the Directors and members of
Ovarian Cancer Action (continued)
Opinion on financial statements
In our opinion the financial statements:
• give a true and fair view of the state of the charitable company’s affairs as at 31 March 2013 and of
its incoming resources and application of resources, including its income and expenditure, for the
year then ended;·
• have been properly prepared in accordance with United Kingdom Generally Accepted Accounting
Practice; and
• have been prepared in accordance with the requirements of the Companies Act 2006, the Charities
and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland)
Regulations 2006 (as amended).
Opinion on other matter prescribed by the Companies Act 2006
In our opinion the information given in the Directors’ Annual Report for the financial year for which the
financial statements are prepared is consistent with the financial statements
Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Companies Act 2006 and the
Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our
opinion:
• the charitable company has not kept proper and adequate accounting records or returns adequate
for our audit have not been received from branches not visited by us; or
• the financial statements are not in agreement with the accounting records and returns; or
• certain disclosures of directors’ remuneration specified by law are not made; or
• we have not received all the information and explanations we require for our audit.
Kevin Maddison FCCA Senior Statutory Auditor
Wilson Wright LLP
Chartered Accountants and Statutory Auditors
Thavies Inn House
3-4 Holborn Circus
London, EC1N 2HA
Date: 16 September 2013
20
Unrestricted Restricted Total Total Notes Funds Funds 2013 2012 £ £ £ £
Incoming resources
Incoming resources from generated funds: Voluntary income 3 1,687,534 632,705 2,320,239 1,844,982 Investment income - interest receivable 14,588 - 14,588 3,620
Total incoming resources 1,702,122 632,705 2,334,827 1,848,602
Resources expended
Costs of generating voluntary income 4 343,258 - 343,258 329,144 Charitable activities 5 1,233,936 469,000 1,702,936 1,457,796 Governance costs 7 62,676 - 62,676 37,017
Total resources expended 1,639,870 469,000 2,108,870 1,823,957
Net movement in funds for the year/ net income for the year 62,252 163,705 225,957 24,645
Total funds at 1 April 2012 1,426,538 4,000 1,430,538 1,405,893
Total funds at 31 March 2013 15 1,488,790 167,705 1,656,495 1,430,538
OVARIAN CANCER ACTION
Statement of Financial Activities (including Income and Expenditure
account) for the year 31 March 2013
21
Notes 2013 2012 £ £
Fixed Assets
Tangible assets 9 13,683 20,524 Investment 10 1 1
13,684 20,525
Current assets
Debtors 11 756,338 297,228
Cash and short term deposits 2,218,839 1,753,202
2,975,177 2,050,430
Creditors: amounts falling due within one year 12 1,078,366 640,417
Net current assets 1,896,811 1,410,013
Total assets less current liabilities 1,910,495 1,430,538
Creditors: amounts falling due after
more than one year 12 254,000 -
Net assets 1,656,495 1,430,538
Represented by:
Unrestricted funds
General fund 15(i) 105,790 195,704
Designated funds 15(ii) 1,383,000 1,230,834
1,488,790 1,426,538
Restricted funds 15(iii) 167,705 4,000
1,656,495 1,430,538
Approved by the Board of Directors and authorised for issue on 9 September 2013
Allyson J Kaye Chair of the Board Company Registration No. 5403443
OVARIAN CANCER ACTION
Balance Sheet as at 31 March 2013
22
1/ Basis of accounting
The accounts are prepared under the historical cost convention and in accordance with the Companies
Act 2006, the applicable Accounting Standards in the United Kingdom, the Statement of Recommended
Practice ‘Accounting and Reporting by Charities’ – 2005, the Charities Act 2011, the Charities and Trustee
Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended).
2/ Accounting policies
2.1 Incoming resource
Voluntary income and donations are accounted for when the charity is entitled to receipt and the
amount can be measured with reasonable certainty. The income from fundraising ventures is shown
gross, with the associated costs included in fundraising costs. Other income is accounted for on a
receivable basis.
2.2 Donated Services
Donated services are included in incoming resources when the benefit to the Charity is reasonably
quantifiable and measurable. They are valued by the Directors at the amount the charity would have
been willing to pay for the services on the open market.
2.3 Value added tax
Value added tax is not recoverable and as such is included in the relevant costs in the Statement of
Financial Activities.
2.4 Resources expended
Expenditure is recognised on an accruals basis.
- Costs of generating funds comprise the costs associated with attracting voluntary income and the
costs associated with fundraising purposes.
- Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities
and services for its beneficiaries. It includes both costs that can be allocated directly to such
activities and those costs of an indirect nature necessary to support it.
- Governance costs include those costs associated with meeting the constitutional and statutory
requirements, and strategic management of the charity.
2.5 Pensions
The Charity contributes to defined contribution schemes for the benefit of its employees.
Contributions payable are charged to the statement of financial activities in the year they are payable.
2.6 Grants payable
Grants are provided for when approved by the directors and written acceptance has been received
from the grantees.
2.7 Costs allocation
Costs are allocated between the expenditure categories of the Statement of Financial Activities
on a basis designed to reflect the use of the resource. Costs other than support costs relating to
a particular activity are allocated directly. Support costs (staff costs) are allocated to the expense
categories according to the role of the individual; the apportionment is disclosed in note 6.
2.8 Tangible fixed assets
Depreciation is provided on a straight line basis at the following annual rates in order to write off each
asset over its estimated useful life:
Office equipment 20%
OVARIAN CANCER ACTION
Notes to the Financial Statements for the year ended 31 March 2013
23
2.9 Fund accounting
The following funds are held by the charity:
- unrestricted general funds – these are funds which can be used in accordance with the charitable
objects at the discretion of the Board of Directors.
- unrestricted designated funds – these are funds set aside by the Board of Directors out of
unrestricted general funds for specific future purposes or projects.
- restricted funds – these are funds that can only be used for particular restricted purposes within the
objects of the charity. Restrictions arise when specified by the donor or when funds are raised for
particular restricted purposes.
2.10 Foreign currency translation
Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the average rate for the month in which the transaction occurred. All differences are taken to the net movement in funds.
3 Voluntary Income Unrestricted Restricted Total Total
2013 2012 £ £ £ £
Charitable trusts 11,850 615,000 626,850 533,546
Third party fundraising 56,069 - 56,069 119,060
Legacies 663,377 - 663,377 95,925
In memoriam 318,310 - 318,310 143,134
Challenge and running events 340,573 - 340,573 448,609
Donated services - - - 90,000
Other donations 297,355 17,705 315,060 414,708
1,687,534 632,705 2,320,239 1,844,982
4 Costs of Generating Voluntary Income 2013 2012 £ £
Staff costs 206,723 189,074
Challenge and running events 56,363 40,261
Other 80,172 99,809
343,258 329,144
OVARIAN CANCER ACTION
Notes to the Financial Statements for the year ended 31 March 2013 (cont)
24
OVARIAN CANCER ACTION
Notes to the Financial Statements for the year ended 31 March 2013 (cont)
5 Charitable Activities
Direct Support Costs 2013 2012 £ £ £ £ Total Total
Grants payable
Ovarian Cancer Action Research Centre
Imperial College/Hammersmith Hospital 850,000 - 850,000 764,350 Research grants underspend (71,186) - (71,186) (105,350)
778,814 - 778,814 659,000BriTROC Research programme 380,000 - 380,000 - 1,158,814 - 1,158,814 659,000Other charitable activities
Research management & admin: staff costs - 38,382 38,382 47,367
Research Centre review - - - 15,029 Awareness activities 350,977 103,396 454,373 589,335
Donated services - Awareness advertising - - - 90,000 Giving a Voice activities 2,833 48,534 51,367 57,065
1,512,624 190,312 1,702,936 1,457,796
Reconciliation of grants payable 2013 2012 £ £
Commitments at 1 April 2012 521,577 971,404
Commitments made in the year 1,230,000 764,350 Research grants underspend (71,186) (105,350)Grants paid during the year (478,403) (1,108,827)
Commitments at 31 March 2013 1,201,988 521,577
Commitments at 31 March 2013 are payable as follows:
Within 1 year (Note 12) 947,988 521,577After more than 1 year (Note 12) 254,000 -
1,201,988 521,577
6 Support Costs Allocation* 2013 2012 £ £
Staff costs including recruitment
Costs of generating funds 206,723 189,074
Charitable activities 190,312 256,492
Governance 49,136 25,617
446,171 471,183
* Finance functions were partly provided to the Charity pro bono.
25
7 Governance costs 2013 2012 £ £
Staff costs 49,136 25,617Auditor’s fees 7,800 7,800Auditors other fees - accountancy 5,740 3,600
62,676 37,017
8 Directors and employee information
The average full time equivalent number of persons employed by the Charity during the year was 11 (2012-10).One member of staff (2012 – none) was paid in the band £80,001 - £90,000.One trustee was reimbursed £20 (2012 - £755) for travelling and subsistence expenses. 2013 2012 £ £
Amounts paid to employees of the Charity during the year:Salaries and wages 383,225 397,170Pension Costs 5,879 -Social security costs 38,173 38,973
427,277 436,143
9 Tangible fixed Assets Office Equipment £
Cost At 1 April 2012 and at 31 March 2013 34,206
Depreciation At 1 April 2012 13,682 Charge for the year 6,841
At 31 March 2013 20,523
Net book values At 31 March 2013 13,683
At 31 March 2012 20,524
10 Fixed Asset Investment Shares in subsidiary undertaking £
Cost At 1 April 2012 and 31 March 2013 1The charity owns the entire issued share capital of Ovarian Cancer Action Trading Limited.The company has not traded since incorporation.
11 Debtors 2013 2012 £ £
Legacy income 327,175 - Accrued income 417,474 287,328Prepayments 11,689 9,900
756,338 297,228
Debtors include amounts totalling £53,334 (2012 – £nil) receivable after more than one year
12 Creditors amounts falling due within one year 2013 2012
£ £
Trade creditors 86,438 102,571
Social security and other taxes 23,055 2,859
Grants not yet paid 947,988 521,577
Accruals 20,885 13,410
1,078,366 640,417
Amounts falling due after more than one year. Grants not yet paid 254,000 -
OVARIAN CANCER ACTION Notes to the Financial Statements for the year ended 31 March 2013 (cont)
26
OVARIAN CANCER ACTION
Notes to the Financial Statements for the year ended 31 March 2013 (cont)
13 Financial Commitments
At 31 March 2013 the Company was committed to making the following payments under non-cancellableoperating leases in the year ended 31 March 2014. Land & buildings
2013 2012 £ £
Operating leases which expire: Between 2 and 5 years 39,600 39,600
14 Pension Costs
The charity contributes to a defined contribution pension scheme in respect of one member of staff who was paid in the band of £80,001 - £90,000. The assets of the scheme are held separately from those of the charity in independently administered funds. The pension cost charge representing contributions payable by the charity to the funds amounted to £5,879 (2012 - £nil). This amount remained unpaid at 31 March 2013.
15 Funds
(i) General fund £At 1 April 2012 195,704Net income for year 62,252 Transfer to designated fund (152,166)
At 31 March 2013 105,790
(ii) Designated funds £At 1 April 2012 1,230,834 Transfer from general fund 152,166At 31 March 2013 1,383,000
Designated funds are in respect of planned new research work at the Ovarian Cancer Action Research Centre in 2013/2014, awards for successful innovative research applications into either the understanding or treatment of ovarian cancer and a genetic and hereditary ovarian cancer campaign.
(iii) Restricted funds
As at Movements in funds As at 1.4.2012 Incoming Outgoing 31.3.2013 £ £ £ £
Ovarian Cancer Research Research Centre, Imperial College - 552,350 (392,350) 160,000 BriTROC - 8,650 (8,650) - Symptoms Awareness 4,000 71,705 (68,000) 7,705
4,000 632,705 (469,000) 167,705
16 Analysis of fund balances between the net assets Restricted Unrestricted Funds Total General Designated £ £ £ £
Fixed assets - 13,684 - 13,684 Current assets less liabilities 167,705 92,106 1,383,000 1,642,811
167,705 105,790 1,383,000 1,656,495
27
The Board of Directors would like to thank all of Ovarian Cancer Action’s
partners, funders, volunteers and supporters across the world without whose
generosity, time and positivity we would not be able to continue our work.
Supporters and fundraisers
We would sincerely like to thank the many kind and generous individuals who have supported the
charity in the past year. Through donations large and small, time and creative ideas, they have
enabled us to deliver our largest income to date.
As our supporter base grows we regret that we are unable to list everyone individually but every
contribution is hugely valued.
• Cary Cochrane, creator of the Walkathong
• The women who participated in Women V Cancer challenge
• Loretta Oliver and family
• Florence Wilks
• Tessa Jane Sidey and family
• Carol Ann Sargent and family
• Dan Tsantilis
• Jane Daly, Stephen Reynolds and family
Trusts and foundations
Sylvia Aitken Charitable Trust,
The February Foundation,
The Freemasons’ Grand Charity,
Isle of Man Anti-Cancer Association,
The George John and Sheilah Livanos Charitable Trust,
The Henry Lumley Charitable Trust,
The Newby Trust,
The Austin & Hope Pilkington Trust,
Rosetrees Trust,
The Steel Charitable Trust
The Maurice Wohl Charitable Foundation.
Corporate supporters
Roche
MSD
BDO International
BlackRock
Paperchase
Oliver Bonas
Marks & Spencer PLC
We are also grateful to the numerous additional individuals and organisations who have supported the
charity with a variety of donations and gift in kind for our events, auctions and raffles.
We would like to acknowledge and thank our volunteers who have helped us throughout the year.
28
ACKNOWLEDGMENTS
